ENVB Enveric Biosciences Inc: רווח נקי למניה ב-12 החודשים האחרונים

Efficient cross-border logistics of biological raw materials provide Enveric Biosciences (ENVB) with high margins and protection against customs risks. The TTM YoY earnings per share trend demonstrates market equilibrium, with the value fixed at 86.20. The current share price already prices in early R&D costs, while future growth depends on the success of psychedelic trials and the patent protection of new molecules.
Enveric Biosciences Inc - פילוחים אנליטיים ומדדי מפתח (ENVB)

Stress testing assets requires an analysis of actual profit dynamics to assess capital stability. Enveric Biosciences (ENVB) is aggressively developing proprietary psychedelic molecules amidst fierce industry competition. The EPS YoY (TTM) percentage growth history measures the annual change in net income per share, reflecting the business's scaling pace. This momentum demonstrates the efficiency of R&D investments relative to market risks. High volatility in this metric confirms the speculative nature of the startup.